GRAL
GRAIL, Inc.
Healthcare — Diagnostics & Research
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Price History
Fundamentals
| Market Cap | $2.92B |
| P/E Ratio (TTM) | - |
| Forward P/E | -7.01 |
| EPS (TTM) | $-10.30 |
| Dividend Yield | - |
| Profit Margin | -253.22% |
| Revenue Growth | 28.10% |
| ROE | -16.09% |
| Debt/Equity | 2.04 |
| Recommendation | Buy 2.1 |
| Analyst Target | $66.00 |
| Analysts | 8 |
| Next Earnings | Aug 5, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 73.4 |
| Beta | 3.16 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $118.84 |
| 52-Week Low | $29.95 |
| 50-Day Avg | $61.30 |
| 200-Day Avg | $72.62 |
| Avg Volume | 746.6K |
| Volume | 389.1K |
Performance Analysis
NEUTRALGRAL presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:12 UTC
Back to Screener Export Report